Consultant
Senior Registrar The Northlern Ireland Radiotheerapy Centre The problenm of how to deal with an individual case of advanced carcinoma of the breast is one that confronts every clinician working on malignant disease. We feel that such patients should always be treated initially by simple hormone administration for a trial period to determine whether they can be controlled in this way. If this is not possible they should then be considered for endocrine surgery or chemotherapy. The results of chemotherapy with thiotepa (triethylene thiophosphoramide) in a group of 46 such patients are reviewed below. Watson and Turner (1959) reported the use of thiotepa and testosterone given concurrently in breast cancer, having obtained the remarkable objective remission rate of 85%. Seven out of 34 of their patients were stage 2 cases; but, even if these are excluded, 23 of the remaining 27 patients with metastatic disease were said to show some measure of control. Cree (1960) , using the same technique, had similar results in 17 patients.
We were anxious to see if we could repeat these results and so develop the treatment as an alternative to endocrine surgery. We also hoped to find points in the patients' history and in their general pattern of disease which might guide us in assessing the chances of response.
Material and Methods of Treatment All the patients considered for the treatment were suffering from progressive metastasizing breast cancer. All had had a trial of hormone therapy and had either responded initially and subsequently relapsed or had failed to respond. If there was clinical or biochemical evidence of liver involvement or the general condition of the patient was very poor, thiopeta therapy was withheld. All deaths occurring in less than one month from the end of treatment were regarded as being caused by the drug.
A patient classified as receiving benefit from treatment had to show evidence of objective remission on radiological, photographic, or clinical findings. Before a positive result was claimed such improvement had to be maintained for at least three months after the last dose of thiotepa had been given. Subjective remissions were not considered significant, as the large doses of testosterone produced feelings of wellbeing in almost all the patients, even in those in whom the disease was obviously advancing. Before starting treatment relevant photographs and radiographs were taken and liverfunction tests and a full blood count were performed.
The doses of thiotepa and testosterone followed closely those suggested by Watson and Turner, though in our experience it was not possible to give some of the larger quantities they used. The scheme was as follows:
1. Testosterone propionate. 100-200 mg. daily five days a week by intramuscular injection. This substance was continued until the patient's discharge from hospital.
2. Thiotepa. After the first five injections of testosterone 15 mg. of thiotepa was given by intramuscular injection. This was followed on alternate days by 30 mg. until a maximum of 285 mg. had been given. If the white-cell count fell below 2,000/c.mm. or the platelets below 100,000/c.mm. the drug was stopped.
3. Full blood counts were carried out every second day.
4. Some cases had two courses of treatment.
Results
Pattern of Treatment Response (Table I) A total of 46 patients were initially selected for treatment, and five of these died as a result of it. This mortality of 11% was comparable to what we have experienced with hypophysectomy. Of the 41 patients who survived treatment 17 had an objective remission as judged by the criteria already given. This was 37% of the total number of patients in the series and 41 % of those who survived the treatment. The mean duration of the period of control was 7.5 months and the mean survival after the disease had become reactivated was 4.5 months. It was of interest that this latter figure was almost the same as the duration of survival in those who failed to show any response. At present, treatment of metastatic breast cancer is frustrating from many points of view, not least of these being the usually unpredictable way patients respond to any given approach. A search was therefore made for any details in the history or in the previous behaviour of the tuimour which might serve as a guide to the outcome of treatment. The positive findings are set out in Table II . From the Table it will be seen that the most important single factor determining response to treatment was the speed at which the tumour progressed.
Those cases with a time-interval of more than one year between the first appearance of their primary tumour No subjective symptoms due to thiotepa were complained of, but a number of women developed signs of intolerance to testosterone. These included nausea, abdominal discomfort, and oedema of the legs, but they usually abated when dosage of the latter drug was reduced by half.
In general, the quantity of thiotepa given depended on the rate of fall of the white-cell and platelet counts. This usually began about the end of the second week of treatment, which was stopped when the white cells fell to 2,000/c.mm. and the platelet count to 100,000/c.mm., as already described. This trend continued for ten to fourteen days after the drug was stopped, often reaching levels far below those generally considered compatible with immunity to infection and an intact capillary system. We were interested to see the infrequency of petechial haemorrhages and infection in patients with white-cell counts below 300/c.mm. and platelet counts of less than 30,000/c.mm.
In seven patients almost total ablation of the bonemarrow took place. Four of these had foetal liver transfusions with a successful outcome in one which has already been reported (Bridges et al., 1960 The numbers were small, but there appeared to be little relation between any previous response to testosterone and that subsequently obtained by the method described.
Treatment of Marrow Depression
This will be discussed more fully in a subsequent publication. It was observed that, apart from the treatment fatalities noted, remarkable degrees of white-cell and platelet depression were compatible with subsequent spontaneous return of blood counts to normal.
Treatment, if indicated, consisted of: (1) Cessation of all injections. Testosterone (sublingual) was continued by the oral route and no further thiotepa was given. (2) A broad-spectrum antibiotic was used even when efficient barrier-nursing was practicable. (3) Prednisone 15-20 mg. daily. It was recognized that this treatment was empirical. (4) Foetal liver suspension as already mentioned.
Discussion
We have not been able to obtain the same satisfactory results in advanced breast cancer as those reported by Watson and Turner (1959) or by Cree (1960) , but it is clear that useful control of the disease was possible in some patients (Table D) . Taking the group as a whole, one patient in three had objective benefit for an average period of 7.5 months. It could be argued that this prolongation of life is apparent rather than real, being merely longer survival in a group of patients with a more slowly evolving type of disease. The only absolute answer to this would be a controlled clinical trial, which has not been done. It was noted, however, that the patients did not merely survive but showed evidence of objective remission, as already defined, and it is hard to believe that such improvement would not be associated with a true increase in survival-time. Had we included as remissions periods of improvement lasting less than three months from the last injection our figures would have been better, but we felt that responses of such short duration could not justify the protracted and hazardous treatment.
The purely subjective improvement made by many patients who failed to benefit objectively was also of value, but might have been the result of the large amounts of testosterone used and could probably be obtained by this drug alone.
From these observations it can be concluded that the frequency and duration of objective remissions were disappointing in view of the original optimistic reports of Watson and Turner (1959) . However, despite the high mortality from the drug (11%), an objective remission in one-third of patients whose only alternative treatment was major endocrine surgery was not entirely unsatisfactory. The treatment therefore has a part to play in the overall management of advanced breast cancer, and an attempt must be made to define just what this is.
Although the Joint Committee of the American Association (1961) found little difference between the results obtained by hypophysectomy and those by adrenalectomy, other workers have shown hypophysectomy to be the superior procedure (Atkins et al., 1960; Ray and Pearson, 1960) , and we feel that comparison with this latter operation is more relevant. As practised in Belfast, this combines surgical removal of the pituitary with intrasellar radiation, using yttrium 90 in wax (Edelstyn et al., 1958) and has a mortality of 11% and an objective remission rate of 58 % with a mean duration of 20 months. The comparable figures from thiotepa were 11 %, 41%, and 7.5 months. In addition a number of patients are in their fourth, fifth, and sixth years of remission after hypophysectomy, while none of the thiotepa group has been controlled more than 15 months. In view of these results there is little doubt which method of treatment is the better.
It was hoped that the two remedies might have been effective in different groups of patients. Table II shows that a good response to thiotepa could be expected when the patient was pre-menopausal and had a slowly evolving disease process with distant metastases. Selection of cases for hypophysectomy may be based on similar criteria (MacAlister et al., 1961 It must be emphasized that the criteria for the selection of patients for any method of palliation are impreeise and can serve only as a guide. It is never possible to say that a patient will not respond; and, conversely, another patient will have all the factors likely to make for response and yet disappoint. It is therefore easy to understand how a decision may be influenced by the patient's particular circumstances and personality.
It might be thought that the large quantity of testosterone given with the thiotepa played a part in producing the responses observed. The possibility cannot be excluded, and it is probable that this substance was partly responsible for the subjective benefit so often seen. If, however, testosterone was also responsible for the objective remissions produced, one would expect some relationship to exist between response to it at a previous stage and subsequent benefit from thiotepa (Table IV) Table III shows that a rapid fall in the blood count to levels necessitating cessation of therapy did not give much information about the ultimate depth of marrow depression. Thus 13 (56%) out of 23 patients able to tolerate doses between 166 and 225 mg. showed eventual severe depression, while those given 226 to 285 mg. showed a similar result. It must be concluded that about half the cases treated will suffer a dangerous degree of marrow depression, and it is difficult either to prevent it or to predict when it will occur. The only way to make treatment safer would be to raise the white-cell and platelet levels at which treatment is stopped. It is likely that this would reduce the number of remissions.
We cannot recommend second courses of treatment. The mortality produced (5 deaths out of 13 cases) was high, though it must be admitted that these cases had very advanced disease and were in poor general condition.
Summary The results of treatment with thiotepa and testosterone in 46 patients suffering from advanced breast cancer have been presented. The mortality rate was 11%, and an overall remission rate of 37 %, lasting an average of 7.5 months, was obtained. It appeared that premenopausal women with a slowly evolving disease and metastases in bone were more likely to respond to this form of therapy. The hazards and protracted nature of treatment were comparable to those from hypophysectomy, but it was concluded that the results were inferior to those of the operation.
